Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion
Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative
breast cancer (TNBC) 1 . The extracellular matrix (ECM) contributes to immune …
breast cancer (TNBC) 1 . The extracellular matrix (ECM) contributes to immune …
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Background Diffuse large-B-cell lymphoma is curable, but when treatment fails, outcome is
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
[HTML][HTML] Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
J Vadakekolathu, C Lai, S Reeder, SE Church… - Blood …, 2020 - ashpublications.org
Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK …
…, A Rittmeyer, JD Patel, J von Pawel, C O'Hear, C Lai… - Lung cancer, 2019 - Elsevier
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with
and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. …
and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. …
[HTML][HTML] Recent drug approvals for acute myeloid leukemia
C Lai, K Doucette, K Norsworthy - Journal of hematology & oncology, 2019 - Springer
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
incidence that increases with age, and a generally poor prognosis. The disease is clinically …
[HTML][HTML] Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry
New techniques for single-cell analysis have led to insights into hematopoiesis and the immune
system, but the ability of these techniques to cross-validate and reproducibly identify the …
system, but the ability of these techniques to cross-validate and reproducibly identify the …
Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia
…, JP Lash, RE Molokie, B Oza, C Lai… - British journal of …, 2014 - Wiley Online Library
To evaluate the association between haemoglobinuria and chronic kidney disease ( CKD )
in sickle cell anaemia ( SCA ), we analysed 356 adult haemoglobin SS or Sβ o thalassaemia …
in sickle cell anaemia ( SCA ), we analysed 356 adult haemoglobin SS or Sβ o thalassaemia …
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
ME Percival, C Lai, E Estey, CS Hourigan - Blood reviews, 2017 - Elsevier
The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or
bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and …
bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and …
[HTML][HTML] Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation
MA Lopez-Ramirez, CC Lai, SI Soliman… - The Journal of …, 2021 - Am Soc Clin Investig
Cerebral cavernous malformations (CCMs) are common neurovascular lesions caused by
loss-of-function mutations in 1 of 3 genes, including KRIT1 (CCM1), CCM2, and PDCD10 (…
loss-of-function mutations in 1 of 3 genes, including KRIT1 (CCM1), CCM2, and PDCD10 (…